LongRiver portfolio company, Ouro Medicines, has entered into a definitive agreement to be acquired by Gilead Sciences. LongRiver Investments participated in the company’s Series A financing in 2025, and has been pleased support the team in its development. The proposed transaction is valued at up to $2.175 billion.
LongRiver portfolio company, Ouro Medicines, has entered into a definitive agreement to be acquired by Gilead Sciences.
Ouro Medicines is a clinical-stage biotechnology company focused on developing T cell engager therapies for autoimmune diseases. Its lead progarm OM336 (gamgertamig), is designed to enable rapid and deep B-cell depletion following a limited subcutaneous treatment course.
LongRiver Investments participated in the company’s Series A financing in 2025, and has been pleased support the team in its development. The proposed transaction is valued at up to $2.175 billion.
